RESEARCH AREA

Amyotrophic lateral sclerosis (ALS)

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Completed Clinical Trial

2022: Himalaya study (Phase II)

For more information contact Victorine Sikati Foko Recruitment will start in few next weeks

Completed Clinical Trials

2023 BIAL (Phase II)
2021: BN42358 study (Phase IIb)
2014: iSTEP study (Phase III)
2011: CONFIDENT-PD study (Phase II)
2010: AFQ056A2217 study (Phase II)
2010: AFQ056A2208 study (Phase II)

Symptoms & Cause

Symptoms generally develop slowly over years. The progression of symptoms is often a bit different from one person to another due to the diversity of the disease. People with PD may experience:

Tremor, mainly at rest and described as pill-rolling tremor in hands. Other forms of tremor are possible

  • Bradykinesia
  • Limb rigidity
  • Gait and balance problems

The cause remains largely unknown. Although there is no cure, treatment options vary and include medications and surgery. While Parkinson’s itself is not fatal, disease complications can be serious.

Diagnose & Treatment

There is no “one way” to diagnose Parkinson’s disease (PD). However, there are various symptoms and diagnostic tests used in combination. Making an accurate diagnosis of Parkinson’s — particularly in its early stages — is difficult.

There is no standard treatment for Parkinson’s disease (PD). Treatment for each person with Parkinson’s is based on his or her symptoms. Treatments can include medications, physical therapy, surgical options, medical marijuana, clinical trials, lifestyle modifications, like getting more rest and exercise.

There are many medications available to treat Parkinson’s symptoms, although none yet that reverse the effects of the disease. It is common for people with PD to take a variety of these medications — all at different doses and at different times of day — to manage symptoms.

Importance of clinical research

Scientists and doctors are working together to find a treatment or prevention technique. The clinical research will help to attract the attention of the federal and state government as well as the pharmaceutical industry to the growing need and urgency in addressing PD. This is an important first step to better understanding who develops PD and why. We participate in a number of clinical trials aiming to create advancements for the treatment of Multiple Sclerosis, Stroke, Parkinson’s, Alzheimer’s and Glioblastoma Multiforme (GBM). Our participation allows us to offer many treatments long before they become available to a majority of specialists, giving patients an opportunity to choose from a wide range of care that, while experimental in nature, may possibly be more effective. Cutting edge treatments aren’t the only reason we conduct clinical trials, nor are they the only reason patients decide to participate. Our involvement gives us the opportunity to develop better protocols and, most importantly, to help advance the treatments themselves. When it comes to Neurological diseases, large strides have been made in recent years; results that would have been impossible without the participation of Doctors, Nurses and, most of all, patients.

Sclérose Latérale Amyotrophique (SLA)

La sclérose latérale amyotrophique (SLA) est une maladie neurodégénérative rare qui touche les systèmes nerveux central et périphérique, avec une incidence estimée à 1 à 3 cas par 100 000 personnes par an.

Participer

Sclérose Latérale Amyotrophique (SLA)

La SLA se caractérise par une faiblesse progressive, une atrophie musculaire et une raideur des membres ou des muscles bulbaires, qui contrôlent la parole et la déglutition. Chez certaines personnes, on observe aussi des changements cognitifs et des altérations de la personnalité. La SLA est une affection fatalement évolutive, la plupart des patients survivant en moyenne de 3 à 5 ans après le diagnostic. La cause et les mécanismes de la maladie demeurent encore mal compris.

Les médicaments actuellement disponibles, comme le riluzole et l’edaravone (Radicava), peuvent prolonger modestement la survie, mais n’arrêtent pas la progression ni n’améliorent la qualité de vie. Les traitements de soutien, notamment la physiothérapie et l’ergothérapie (voir [Réadaptation neurologique]), l’assistance ventilatoire nocturne et le soutien nutritionnel par sonde d’alimentation, restent la base de la prise en charge. La recherche se poursuit, tant pour les traitements symptomatiques que pour les thérapies modifiant l’évolution de la maladie. La neuromodulation non invasive par [Stimulation magnétique transcrânienne répétitive (SMTr)] a montré qu’elle pouvait atténuer certains symptômes de la SLA, notamment la faiblesse et la spasticité.

Cependant, la [SMTr] est encore considérée comme un traitement expérimental et n’est pas couverte par les régimes publics d’assurance maladie (RAMQ/OHIP).

Completed Clinical Trial

2022: Himalaya study (Phase II)

Études en recrutement

Veuillez vous informer. Au moment de la rédaction, la CNO n’a pas d’essai en recrutement.

Études en cours

Veuillez vous informer. Au moment de la rédaction, la CNO n’a pas d’essai en cours.

Études terminées

2022: Étude Himalaya (Phase II)